Equities

GVS SpA

GVS SpA

Actions
IndustrialsGeneral Industrials
  • Price (EUR)5.23
  • Today's Change0.00 / 0.00%
  • Shares traded123.37k
  • 1 Year change-4.91%
  • Beta0.4925
Data delayed at least 15 minutes, as of Nov 25 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GVS SpA is an Italy-based manufacturer of filters and components for applications in the healthcare, life sciences, automotive, appliance, safety, commercial and industrial filtration. Its offering includes seven product lines: Healthcare, Laboratory, Mobility, Air Safety, Appliance, Personal Safety and Membranes. Each product line provides a suite of customizable solutions specifically related to each market. Additionally, the Company offers tailormade product and process development services, which cover all the project stages, including product and process design, validation, up to the mass production for large quantities. It is active globally.

  • Revenue in EUR (TTM)433.30m
  • Net income in EUR17.36m
  • Incorporated1992
  • Employees4.39k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
RaySearch Laboratories AB (publ)101.40m15.19m461.96m414.0040.268.6912.794.565.105.1034.0923.650.60235.513.293,005,152.009.021.2913.691.8891.0690.5714.972.551.27108.610.370669.0021.1610.26243.060.7648-1.31--
Advanced Medical Solutions Group plc157.04m13.33m546.50m1.50k41.171.8820.313.480.0510.0510.60111.120.39771.704.91154,244.703.386.543.647.0654.4556.758.4914.826.80--0.270225.851.514.23-22.14-6.7115.6612.32
Surgical Science Sweden AB74.58m16.77m644.51m270.0039.201.7029.528.643.793.7916.8587.190.17691.566.803,307,035.003.984.494.214.7868.6570.0622.4923.753.73--0.000.0010.0168.1424.47--38.57--
Revenio Group Oyj102.08m19.01m724.26m230.0037.487.1029.867.100.72040.72043.863.810.78344.938.17472,574.1014.6714.3317.0917.9049.2950.7318.7221.131.5134.570.127655.81-0.412525.80-12.1518.7217.676.30
Arjo AB (publ)969.97m44.33m729.04m6.85k18.171.185.610.75161.881.8841.0528.870.71494.546.781,644,896.003.263.554.625.5543.6444.014.565.410.6263.970.407343.0110.035.976.9010.15-8.8910.35
Paul Hartmann AG2.38bn59.53m741.16m10.05k12.530.65994.410.31116.7616.76671.22318.251.181.995.45234,407.103.193.874.195.3458.0056.712.702.981.317.680.208242.751.802.12-21.37-18.495.952.71
Medartis Holding AG236.86m4.34m748.65m829.00173.582.6727.213.160.30880.308817.0420.070.53770.56744.96265,720.500.98450.19191.130.215380.5382.331.830.35423.154.030.32270.0015.9611.81110.70-31.825.37--
Draegerwerk AG & Co KGaA3.35bn113.44m800.33m16.56k6.880.54413.100.23916.056.05178.4576.451.112.474.97205,014.403.803.265.614.8743.5144.163.413.051.106.830.170411.3810.785.39271.0533.872.6455.73
GVS SpA433.30m17.36m907.85m4.39k52.252.6014.582.100.10010.10012.482.010.45222.136.9798,792.301.817.352.3010.8255.3558.744.0012.440.97763.510.5369--9.5815.25-43.37-9.9716.08--
El En SpA659.63m49.76m979.76m2.11k19.172.6615.641.490.62230.62238.254.490.91411.773.69316,823.507.027.4312.8913.5240.0338.837.687.631.19--0.1845--2.7814.88-12.4723.49-13.40--
Biotage AB184.50m22.29m1.07bn675.0048.453.2728.235.813.213.2126.5647.600.43121.597.223,155,786.005.2110.746.0512.7762.6761.4012.0815.751.1543.880.061640.1119.5415.50-8.217.9714.051.30
ChemoMetec A/S54.69m18.27m1.11bn173.0062.0314.9553.6620.267.837.8323.4432.480.61120.7456.972,357,630.0020.4227.9624.4035.1078.8079.5733.4135.023.76--0.0073144.08-8.2218.37-23.7226.649.97-11.81
Xvivo Perfusion AB65.11m17.72m1.23bn161.0070.607.0251.3618.886.586.5824.0766.130.33251.144.674,691,194.009.051.249.681.3374.4173.1427.214.764.23--0.01170.0043.8826.04398.2948.5721.35--
AddLife AB868.48m10.15m1.34bn2.36k138.533.1614.781.550.96010.960182.1642.090.76253.505.584,351,152.000.90635.311.298.8337.3036.891.195.790.6381.660.514631.736.6231.30-60.428.0044.43-1.89
Data as of Nov 25 2024. Currency figures normalised to GVS SpA's reporting currency: Euro EUR

Institutional shareholders

15.31%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 30 Sep 20247.86m4.49%
Mediolanum Gestione Fondi SGRpAas of 28 Jun 20243.21m1.83%
T. Rowe Price International Ltd.as of 30 Sep 20242.70m1.54%
The Vanguard Group, Inc.as of 06 Nov 20242.48m1.42%
Amundi Asset Management SA (Investment Management)as of 06 Nov 20242.09m1.19%
Invesco Asset Management Ltd.as of 30 Sep 20241.81m1.04%
Degroof Petercam Asset Management SAas of 31 Jul 20241.79m1.02%
Fidelity Management & Research Co. LLCas of 30 Sep 20241.76m1.01%
Fideuram Asset Management SGR SpAas of 31 Oct 20241.66m0.95%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Sep 20231.43m0.81%
More ▼
Data from 28 Jun 2024 - 20 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.